Abstract:This article addresses the feasibility and safety of ICD therapy in patients >80 years of age. Recent trials have expanded the indication for ICD implantation to include an increasing number and variety of patients. The feasibility of ICD implantation in elderly patients has not been adequately studied. A prospectively collected single center ICD database was analyzed to assess the safety and feasibility of ICD implantation in elderly patients. Patients were divided based on age into two groups (group 1: 70-79… Show more
“…More recently, Noseworthy and colleagues [21] examined ICD related complications and survival in 29 octogenarians compared to 183 patients aged 70 to 79 years at the time of ICD implant. Noseworthy et al [21] found no significant differences in the complication rate between both age groups with a perioperative mortality of 0% in both age groups.…”
Section: Cohort Studies Of Elderly Icd Recipientsmentioning
“…More recently, Noseworthy and colleagues [21] examined ICD related complications and survival in 29 octogenarians compared to 183 patients aged 70 to 79 years at the time of ICD implant. Noseworthy et al [21] found no significant differences in the complication rate between both age groups with a perioperative mortality of 0% in both age groups.…”
Section: Cohort Studies Of Elderly Icd Recipientsmentioning
“…In one retrospective study stratifying patients at 65 years of age [29], there was no difference in length of hospital stay after ICD implantation in patients younger or older than 65 years of age. In another retrospective analysis of patients at least 70 years of age receiving ICDs, the complication rate was 6.6% in patients ages 70 to 79 years versus 13.1% in those older than 80 years of age (not statistically signifi cant) [19]. In a database of 31,000 Medicare ICD recipients, 10.8% had one or more complications during their hospital stay for ICD implantation [30•].…”
Section: Procedures Complicationsmentioning
confidence: 99%
“…Retrospective data regarding ICDs in octogenarians was analyzed in those receiving ICDs for secondary prevention [19]. This single-center database compared short-term survival among different age groups (183 patients ages 70-79 years and 29 patients > 80 years).…”
Section: Implantable Cardioverter Defi Brillators: Data In the Elderlymentioning
“…One single center experience with ICD therapy in patients greater than 80 years of age showed at least clinical equivalency between 183 septuagenarians and 29 octogenarians in survival, cause-specific mortality, and procedural complications over a 17-year retrospective review. 57) Another retrospective review reported that in a comparison between 74 patients greater than 75 years of age and 695 younger patients who had all undergone ICD implantation, there was no difference in the incidence of appropriate ICD defibrillations between the two groups. 58) Although this study reported that advanced age was the most powerful predictor of adverse outcomes, the incidence of sudden cardiac death was rare in the elderly ICD group.…”
The management of malignant ventricular arrhythmias will become gradually more important as life expectancy continues to increase. The incidence of sudden cardiac death and overall cardiac mortality is more pronounced in the elderly mainly as a reflection of the higher prevalence of ischemic heart disease. With the exception of beta‐blocker therapy, antiarrhythmic drug therapy has not proven to be effective in the prevention of sudden cardiac death. Implantable cardioverter‐defibrillator therapy has been shown to reduce both overall mortality and arrhythmic death when following current guidelines for implantation and appears to be applicable to any age group when sensible patient selection is implemented. The greater efficacy of this therapy relative to antiarrhythmic therapies supports its expanded use in the elderly population. Such therapy has a similar cost‐effectiveness to other accepted interventions and does not appear to be associated with reduced quality of life or age‐specific complications. The clinical approach to elderly patients at risk of sudden death from ventricular arrhythmias will continue to evolve as new technologies are developed, but the future of ventricular arrhythmia treatment in the elderly will likely emphasize an increasing utilization of both implantable cardioverter‐defibrillator and beta‐blocker therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.